文献速递关节外科骨质疏松与代谢性骨病

晚期膝骨关节炎初次全膝关节置换术前非手术治疗中医疗费用不平等的驱动因素

Drivers of Unequal Healthcare Costs in the Nonoperative Treatment of Late-Stage Knee Osteoarthritis Prior to Primary Total Knee Arthroplasty.
PubMed 文献 · J Arthroplasty · 2022-05-04

基于IBM Watson Health MarketScan数据库2017年1月1日至2019年12月31日的观察性队列研究,纳入24,492例晚期膝骨关节炎患者,分析初次全膝关节置换术前非手术治疗费用。最高支付四分位组(Q4)人均总费用为3735±3049美元,最低支付四分位组(Q1)为137±70美元;Q4与Q1相比,关节内透明质酸注射(IA-HA)使用率变化最大(348倍),支具为10倍,物理治疗(PT)为7倍。处方IA-HA和PT的患者成为高支付患者的可能性分别增加28.3倍和4.8倍。作者结论认为费用不平等由不同管理策略的流行差异驱动,若仅使用与指南一致的治疗可能降低总体医疗支出。

要点

  • Q4组人均非手术费用为3735±3049美元,Q1组为137±70美元。
  • Q4与Q1相比,IA-HA使用率变化为348倍,支具为10倍,PT为7倍。
  • 处方IA-HA和PT的患者成为高支付患者的可能性分别增加28.3倍和4.8倍。

核心结论

  • 晚期膝骨关节炎非手术治疗中医疗费用不平等由不同管理策略的流行差异驱动。
  • 作者认为若仅使用与指南一致的治疗,可能降低总体医疗支出。

研究设计与样本

  • 观察性队列研究,使用IBM Watson Health MarketScan数据库2017年1月1日至2019年12月31日的数据。
  • 纳入24,492例晚期膝骨关节炎患者。
  • 主要结局为非手术操作的支付费用,包括物理治疗(PT)、支具、关节内注射(专业费、透明质酸(IA-HA)、皮质类固醇(IA-CS))、药物(非甾体抗炎药(NSAIDs)、阿片类药物、对乙酰氨基酚)和膝关节特异性影像。

主要发现

  • 最高支付四分位组(Q4)人均非手术护理总支付为3735±3049美元,最低支付四分位组(Q1)为137±70美元。
  • 患者人均每月费用在各四分位组间通常随操作增加而增加。
  • Q4与Q1相比,使用率变化最大的为IA-HA(348倍)、支具(10倍)和PT(7倍)。
  • 处方IA-HA和PT的患者成为更高支付患者的可能性分别增加28.3倍和4.8倍。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the United States, patients with late-stage knee osteoarthritis (OA) often undergo several nonoperative treatments and related procedures prior to total knee arthroplasty. The costs of these treatments and procedures are substantial, and the variation in healthcare costs among different groups of patients may exist. The purpose of this study is to examine these costs and determine the drivers of costs in patients with the highest healthcare expenditure. METHODS: An observational cohort study was conducted using the IBM Watson Health MarketScan databases from January 1, 2017 to December 31, 2019. The primary outcome was the cost of payments for nonoperative procedures which included (i) physical therapy (PT), (ii) bracing, (iii) intra-articular injections: professional fee, hyaluronic acid (IA-HA), and corticosteroids (IA-CS), (iv) medication: nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, and acetaminophen, and (v) knee-specific imaging. RESULTS: Among the 24,492 patients included in the study, the total payments per patient for nonoperative care were $3,735 ± 3,049 in the highest payment quartile (Q4) and $137 ± 70 in the lowest payment quartile (Q1). Per-patient-per-month costs generally increased across quartiles for procedures. Comparing Q4 to Q1, the largest changes in prevalence were found in IA-HA (348×), bracing (10×), and PT (7×). Patients who were prescribed IA-HA and PT had a 28.3-times and 4.8-times greater likelihood, respectively, to be a higher-paying patient. CONCLUSION: Unequal healthcare costs in the nonoperative treatment of late-stage knee OA are driven by differences in prevalent management strategies. Overall healthcare expenditure may be reduced if only guideline-concordant treatments are used.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Nin DZ, Chen YW, Talmo CT, et al. Drivers of Unequal Healthcare Costs in the Nonoperative Treatment of Late-Stage Knee Osteoarthritis Prior to Primary Total Knee Arthroplasty. J Arthroplasty. 2022. PMID: 35525419. doi:10.1016/j.arth.2022.04.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。